Ultragenyx Pharmaceutical Aktie - UP0

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

36,20

Gebot

36,00

Fragen

36,20

Volumen

0,00

0,00 Tagesbereich 0,00

34,20 52-Wochen-Bereich 54,00

Handelsende

36,20

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

160

Finanzvolumen

VWAP

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial...

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial...

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia...

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and...

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with...

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare...

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza®...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	2	5.84795321637	34.2	34.2	34.2	270	34.2	DE
4	-4.599999	-11.2745076293	40.799999	40.799999	34.2	87	35.99351434	DE
12	-4	-9.95024875622	40.2	44.6	34.2	160	39.74967813	DE
26	-12.4	-25.5144032922	48.6	53.5	34.2	145	41.94321401	DE
52	-7.6	-17.3515981735	43.8	54	34.2	173	42.17604646	DE
156	-2.4	-6.21761658031	38.6	54	30.6	163	41.37098973	DE
260	-2.4	-6.21761658031	38.6	54	30.6	163	41.37098973	DE

UP0 - Frequently Asked Questions (FAQ)

What is the current Ultragenyx Pharmaceutical share price?

The current share price of Ultragenyx Pharmaceutical is 36,20 €

What is the 1 year trading range for Ultragenyx Pharmaceutical share price?

Ultragenyx Pharmaceutical has traded in the range of 34,20 € to 54,00 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AMIMedondo Holding AG	0,498 € (91,54%)	101
DBVDBV Technologies	1,154 € (47,95%)	15,11k
36GGBM Resources Limited	0,005 € (42,86%)	1,4k
SNGSingulus Technologies AG	2,30 € (38,97%)	147,64k
4NM1China Evergrande New Energy Vehicle Group Limited	0,0239 € (35,80%)	19k
L7C2Windfall Geotek Inc	0,0055 € (-35,29%)	9,23k
E7TAlexium International Group Share	0,0045 € (-30,77%)	34,05k
2TUTaruga Minerals Limited	0,004 € (-27,27%)	1,09k
E3O1Nexoptic Technology Corp	0,0065 € (-23,53%)	3,24k
20MPMountain Valley MD Holdings Inc	0,0138 € (-23,33%)	500
FMKEcograf Limited	0,168 € (-7,44%)	1,83M
D7GNel ASA	0,2228 € (-1,68%)	1,77M
PF8European Lithium Limited	0,0226 € (-5,83%)	1,75M
DMJDynaCERT Inc	0,1115 € (-7,85%)	960,13k
3CPXiaomi Corporation	6,033 € (-1,82%)	725,72k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Ultragenyx Pharmaceutical Inc (UP0)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

UP0 Neueste Nachrichten

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

UP0 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Ultragenyx Pharmaceutical Inc (UP0) Börsenkurse

Ultragenyx Pharmaceutical Inc (UP0)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

UP0 Neueste Nachrichten

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

UP0 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen